HO WAH Genting Berhad (Bursa stock code 9601) today reports that its wholly-owned subsidiary HWGB Biotech Sdn Bhd’s joint venture partner, US-based E-MO Biology Inc (EBI), has conducted a study to review with a retrospective approach in order to better understand the pattern of the epidemics.
It aims at looking for more evidence to indicate that the children's acquired immunity against SARS-CoV-2 through polio vaccination could set up the model for the benefit of the adult population in prevention against Covid-19.
In the retrospective study, EBI had completed serological study using the ELISA (enzyme-linked immunosorbent assay) method whilst serological studies using the Western Blot method and neutralisation method were 50% completed.
Of the 118 serum samples surveyed in conducting the ELISA test, the results had revealed that paediatric sera showed a slightly higher antigenic activity (ranging from a 20-50% increase), compared to the adult sera group.
It is concluded that the poliovirus immunisation boosts antigenic activity significantly between pre and post immunisation among adults participated.
Moreover, pre-immunisation groups show a lower antigenic activity (30%) than post-immunisation groups.
Of the 81 samples surveyed in conducting the Western blot test, 20 samples tested negative, and 61 tested positive (showing the RNA-dependent RNA polymerase band on Western blot).
As such, the tests above conclude that the polio vaccination increases the production of RdRp antibodies within two weeks.
Lastly, neutralisation tests had shown that when children’s sera and post-immunised adults sera were added to the weakened live Covid-19 virus, the test results showed 100% neutralisation level against the protein of SARS-CoV-2, of which these findings are consistent with the ELISA and Western blot test results described earlier.
Results indicate that polio booster inoculation in adults raises antibodies that recognise SARS-CoV-2 RdRp. The outcome of the study will be published in a scientific journal to further raise the awareness of the polio vaccine function against SARS-CoV-2.
HWGB Biotech Medical and Pharmaceutical Research general manager Dr Yaman Walid Kassab said: “This retrospective study provides evidence that showed polio booster inoculation in adults would induce high level of neutralising antibodies that recognised SARS-CoV-2 RdRp. This is a critical milestone ahead of our first interim analysis from the Phase IV clinical trial.”
Did you find this article insightful?
85% readers found this article insightful